| Literature DB >> 25525360 |
Sakthivel Ramasamy1, Devasier Bennet1, Sanghyo Kim2.
Abstract
This review will present a brief discussion on the recent advancements of bioelectrical impedance cell-based biosensors, especially the electric cell-substrate impedance sensing (ECIS) system for screening of various bioactive molecules. The different technical integrations of various chip types, working principles, measurement systems, and applications for drug targeting of molecules in cells are highlighted in this paper. Screening of bioactive molecules based on electric cell-substrate impedance sensing is a trial-and-error process toward the development of therapeutically active agents for drug discovery and therapeutics. In general, bioactive molecule screening can be used to identify active molecular targets for various diseases and toxicity at the cellular level with nanoscale resolution. In the innovation and screening of new drugs or bioactive molecules, the activeness, the efficacy of the compound, and safety in biological systems are the main concerns on which determination of drug candidates is based. Further, drug discovery and screening of compounds are often performed in cell-based test systems in order to reduce costs and save time. Moreover, this system can provide more relevant results in in vivo studies, as well as high-throughput drug screening for various diseases during the early stages of drug discovery. Recently, MEMS technologies and integration with image detection techniques have been employed successfully. These new technologies and their possible ongoing transformations are addressed. Select reports are outlined, and not all the work that has been performed in the field of drug screening and development is covered.Entities:
Keywords: electric cell-substrate impedance sensing (ECIS); high-throughput screening; impedance-based cell study; real-time drug evaluation; screening of bioactive agents
Mesh:
Year: 2014 PMID: 25525360 PMCID: PMC4266242 DOI: 10.2147/IJN.S71128
Source DB: PubMed Journal: Int J Nanomedicine ISSN: 1176-9114
Figure 1Schematic diagram of the ECIS method working principle.
Notes: (A) Current flow before cell attachment. (B) After cell attachment, the current flows with cells from the surface of Au-sensing electrodes. Cells are grown to confluence on electrodes. The current flow between working electrodes and counter electrodes through cell culture medium, which acted as electrolyte. (C) Different types of ECIS electrode arrays for various applications.
Abbreviations: ECIS, electric cell-substrate impedance sensing; W, well; E, electrode; idf, inter-digitated finger configuration; LE, linear electrode; F, flow array; E+, addition of more electrodes; LE, linear electrode; PC, polycarbonate substrate.
Figure 2A typical electric cell-substrate impedance sensing (ECIS) measurement graph of normal HDFn cell growth response for 20 hours, showing various cellular morphological changes.
Abbreviation: HDFn, human dermal fibroblasts, neonatal cells.
Figure 3Schematic diagram showing various devices and microelectrode chip fabrication types for different studies using bioimpedance platform.
Notes: (A) Real-time optical imaging and impedance measurements. The camera is located above the cell culture chip, which enables provision of real-time imaging. (B) Microfluidic based cell culture sensing system: interdigitated array of electrodes on glass for impedance sensing, a polydimethylsiloxane (PDMS) layer for gradient generation and cell culture, which can provide the concentration dependent cellular behavior. (C) Three-dimensional depiction of a hydrogel chamber of a diffusion cell culture chip integrated with electric cell-substrate impedance sensing (ECIS). (D) Qualitative and quantitative data acquisition using a computer interface with a data monitoring and storage system.
Figure 4Applications of the ECIS system for analysis of cellular behaviors and activity for drug screening studies.
Notes: (A) Barrier function analysis for paracellular pathway and permeability study. (B) Ion channel activity analysis for studying ion transport mechanisms and whether the compound is able to block the channel. (C) Cell signaling analysis for studying cell/extracellular matrix interaction or disruption of signaling pathways. (D) Cell metabolism analysis for studying the differences in growth and metabolic status of cells. (E) Cytotoxicity screening for studying analyte toxicity responses to the cells. (F) Cancer metastasis analysis for studying cancer cell behavior including the potentiality of drugs effects on cells. (G) Photoprotectivity analysis for studying photodamaging and photoprotective effects. (H) Drug resistance analysis for studying drug resistance capacity in various cells, including cancer cells, including cancer cells.
Abbreviations: Acetyl CoA, acetyl coenzyme A; ATP, adenosine triphosphate; ECIS, electric cell-substrate impedance sensing; GPCR, G-protein-coupled receptor.
Figure 5Concentration-response curves for 50% inhibition effects of cells, which is derived from the impedance profile at 12 hours after various analyte concentration administrations.
Note: Basic graph for the half-inhibition (IC50) concentration profile.
Toxicity effects of different compounds on different cell types
| Study | Cells used | Compounds tested | Toxic effects |
|---|---|---|---|
| Nephrotoxicity | Renal tubular cells (HK2) | Cisplatin | ≥3 μM |
| Cytotoxicity | Renal tubular cells (HK2) | Glutathione | ≥2 mM |
| Cardiotoxicity | Cardiomyocytes | Microtubule affinity-regulating kinase inhibitors | Increased gap formation |
| Pulmonary toxicity | Pulmonary endothelial | 12 waterborne industrial chemicals used | Eight chemicals produced toxicity |
| Toxins (neurotoxicity/genotoxicity/hepatotoxicity/dermatotoxicity) | Chinese hamster ovary cells | Cylindrospermopsin, microcystin-LR | No effect at 20 μg/mL |
| Human embryo kidney cells | Cylindrospermopsin, microcystin-LR | No significant effect | |
| Sf9 insect cells | Cylindrospermopsin, microcystin-LR | No effect at 20 μg/mL | |
| Radiation toxicity | Eye cells | Different-colored lights | Time-dependent effect |
Note: Select applications have been covered and do not represent all the work that has been done in this field.
ECIS-based toxicity studies for various compounds and their different perspective uses
| Compounds | Cells used and type of study | IC50 | Applicability | Reference |
|---|---|---|---|---|
| Mercury chloride | v79 cells – toxicity | 77.5 μM | Disinfectant, fungicide | |
| Benzalkonium chloride | v79 cells – toxicity | 14 μM | Preservative, antiseptic | |
| Sodium arsenate | v79 cells – toxicity | 50 μM | Toxicant, insecticide | |
| Cadmium chloride | v79 cells – toxicity | 4 μM | Toxicant (carcinogen) | |
| Doxorubicin | Hela cells | 0.6 μM | Chemotherapy | |
| 5-fluorouracil | Hela cells | 72 μM | Chemotherapy | |
| NH2-PEG rods (p/mL) | MDCK II cells – micromotion | Nontoxic up to ~1.32×1012 | No reduction in micromotion – drug delivery | |
| COOH-PEG rods (p/mL) | MDCK II cells – micromotion | Nontoxic up to 1.32×1012 | No reduction in micromotion – drug delivery | |
| Multi-shell QDs (p/mL) | MDCK II cells – micromotion | ~2×1011 | Reduction in micromotion | |
| CTAB rods (p/mL) | MDCK II cells – micromotion | ~1.20×1011 | Reduction in micromotion | |
| Pure CTAB (μM) | MDCK II cells – micromotion | ~6.4 | Reduction in micromotion | |
| Pure Cd(Ac)2 (μM) | MDCK II cells – micromotion | ~4.3 | Reduction in micromotion | |
Abbreviations: CTAB, cetyl triammonium bromide; ECIS, electric cell-substrate impedance sensing; IC50, half-maximal inhibitory concentration; MDCK, Madin-Darby canine kidney; PEG, polyethylene glycol; QDs, quantum dots.
Prospective studies with examples of drug targeting, identification, and screening using a bioimpedance platform
| Study | Cells used | Analyte used | Observations | Reference |
|---|---|---|---|---|
| Anticancer effects | CaSki and SMMC-7721 | Cisplatin | Half-maximum effect at 4 μM | |
| Hela and RKO | Cisplatin | Half-maximum effect at 16 μM | ||
| A549 cells | ROCK inhibitor | Importance of PLGF in lung cancer | ||
| Breast cancer cells | Eplin-α | Inhibition of cell migration via ERK-dependent pathway | ||
| MDA-MB-435 cells/HUVECs | TGF-β | TGF-β enhanced migration and invasion of MDA-MB-435 cells | ||
| Hepatocellular carcinogenesis cell lines | Leptin | Leptin-induced invasion and inhibition of leptin with JAK/STAT, PI3K, AKT/ERK inhibitors | ||
| Antiviral screening | CHSE214 cells | IPNV/IHNV | Cytopathic effect of viruses on cells in culture | |
| MDCK cells | Influenza A virus | Detection of minute alterations in cells monolayers due to viruses | ||
| Human lung endothelial cells | Bluetongue virus | Role of p38 MAPK, molecular pathway for viral induction of hemorrhagic fevers | ||
| Human bronchial epithelial cells | VEGF/RSV | Endothelial fenestration effects and inhibition of VEGF, RSV with VEGF antibody and palivizumab | ||
| Photoprotectivity | HDFn cells | Quercetin-loaded PLGA nanoparticles, nano-APETE | DPPH radical scavenging activity, synergetic photoprotective effect of nano-APETE | |
| RGCs | Light exposures (white, red, green, blue) | Photooxidative stress due to light exposure | ||
| RGCs | β-carotene, quercetin, agmatine, and glutathione | Phototoxicity, efficacy of drugs | ||
| RGCs | Agmatine and resveratrol | Phototoxicity, efficacy of drugs | ||
| Migration | HDFn cells | Zeaxanthin | Inhibition of PDGF-BB-induced HDFn migrations | |
| BLMVECs | Focal adhesion kinase | Sustained transendothelial migration due to FAK inhibitor | ||
| Motility | Fibroblasts/scleroderma fibroblasts | Different kinds of human sera | Active cellular micromotion | |
| SK-LMS-1, HT29, renal carcinoma cells | Spry2 | Inhibition of cellular movements due to overexpression of Spry2 | ||
| Eukaryotic cells | Chemotactic response of eukaryotic cell | |||
| Metabolism | NIH3T3 cells | CXCR2 | Cellular transformation | |
| Ion channel activities | Mouse fibroblast cells (L929) | Flufenamic acid | Inhibition of connexin hemichannels, prevention of ATP and Ca2+ release | |
| Signaling | Endothelial cells | GPR4 | Role and mediation of GPR4 in cell signaling | |
| HBMECs | Thrombin/PAR1 | Formation of cellular gaps and elevation of permeability | ||
| Anti-cytotoxicity | Renal tubular cells | Glutathione | Recovery shown at ≤2 mM | |
| Renal tubular cells | Sodium thiosulfate | Recovery shown at ≤0.5 mM |
Abbreviations: ATP, adenosine triphosphate; BLMVECs, bovine lung microvessel endothelial cell; DPPH, 2,2-diphenyl-1-picrylhydrazyl; ERK, extracellular signal-regulated kinase; FAK, focal adhesion kinase; HBMECs, human brain microvascular endothelial cells; HDFn, Human dermal fibroblasts, neonatal; HUVECs, human umbilical vein endothelial cells; IHNV, infectious hematopoietic necrosis virus; IPNV, infectious pancreatic necrosis virus; MAPK, mitogen-activated protein kinase; MDCK, Madin-Darby canine kidney; PLGA, poly(lactic-co-glycolic acid); PLGF, placental growth factor; RGCs, retinal ganglion cells; ROCK, Rho-associated protein kinase; RSV, respiratory syncytial virus; TGF, transforming growth factor; VEGF, vascular endothelial growth factor; APETE, Apple peel ethanolic extract.